GNT Pharma
Manufacturing · 51-200 Employees
View Company Info for Free
Overview
Phone Number
+82 3180059910Website
www.gntpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About GNT Pharma
The founding scientists of GNT Pharma have delineated mechanisms underlying nerve cell death occurring in stroke, trauma, and neurodegenerative diseases and discovered therapeutic targets for the interventional therapy that is for medical unmet needs. The drug candidates of GNT Pharma were derived from novel findings that aspirin and sulfasalazine, salicylate derivatives widely used for the treatment of inflammatory diseases, protected neurons as a low affinity NMDA receptor antagonist and antioxidant. Through the rational drug design, GNT Pharma discovered chemical structures essential for neuroprotective effects and has established chemical libraries with promising efficacy and safety that are enough to advance to clinical stage.Explore more
GNT Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GNT Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when GNT Pharma launches new products
GNT Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if GNT Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at GNT Pharma
Funding: Get notified immidiatlly once GNT Pharma has new funding data
Earning: See what the market has to say on GNT Pharma recently announced quarterly report
Check out if GNT Pharma is spiking on competitors!
Check if GNT Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at GNT Pharma
Find 2 more new buyers
Company Profile Activity
Activity Insights
GNT Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GNT Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GNT Pharma.
GNT Pharma Tech Stack
A closer look at the technologies used by GNT Pharma
GNT Pharma News & Media
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™
** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Multinational Phase 3 Clinical Trial protocols confirmed and initiated with leading global stroke research centers * SEOUL, South Korea,...GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)
YONGIN, South Korea, Sept. 19, 2022 (GLOBE NEWSWIRE) -- GNT Pharma Inc. announces that the independent data monitoring committee (IDMC) for ENIS-3 (Efficacy and safety of Nelonemdaz for Ischemic Stroke) has completed a pre-specified interim analysis encompassing 227 acute ischemic stroke patients treated with placebo or nelonemdaz within 8 hours of onset in China. The IDMC concluded that the ENIS-3 trial should continue as planned without modification.GedaCure® von GNT Pharma für die Behandlung von Hunden mit kognitiven Funktionsstörungen zugelassen
YONGIN, Südkorea--(BUSINESS WIRE)--GNT Pharma gab heute bekannt, dass die koreanische Animal and Plant Quarantine Agency (APQA) den Zulassungsantrag für GedaCure®, eine Kautablette mit Crisdesalazine, zur Behandlung von Hunden mit kognitivem Dysfunktion-Syndrom (Cognitive Dysfunction Syndrome, CDS), die unter Desorientierung, veränderter Interaktion mit der Familie, Störung des Schlaf-Wach-Rhythmus, Verunreinigung des Zuhauses und altersbedingten Aktivitätsveränderungen leiden, genehmigt hat. GSamenvatting: GedaCure® van GNT Pharma goedgekeurd voor de behandeling van honden met cognitief disfunctiesyndroom
YONGIN, Zuid-Korea--(BUSINESS WIRE)--GNT Pharma heeft vandaag aangekondigd dat het Korea Animal and Plant Quarantine Agency (APQA) de nieuwe medicijnaanvraag voor GedaCure® heeft goedgekeurd, een kauwtablet met crisdesalazine, voor de behandeling van honden met cognitief disfunctiesyndroom (CDS) die lijden aan desoriëntatie, veranderde interacties met het gezin, verstoring van de slaap-waakcyclus, vervuiling van het huis en veranderingen in activiteit bij het ouder worden. GedaCure® is 's werel
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding GNT Pharma
Sign Up For FreeTo access detailed company insights
The founding scientists of GNT Pharma have delineated mechanisms underlying nerve cell death occurring in stroke, trauma, and neurodegenerative diseases and discovered therapeutic targets for the interventional therapy that is for medical unmet needs. The drug candidates of GNT Pharma were derived from novel findings that aspirin and sulfasalazine,... Read More
